Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 (0.59-0.80) n=13 (16,228/11,279)

Slides:

Advertisements

Similar presentations

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia N Engl J Med Mar 11;362(10): Paul W. Ladenson, M.D., Jens D.

Advertisements

Statins for ischaemic heart disease: Excellence and equity Hackney, Newham & Tower Hamlets.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

CVD risk estimation and prevention: An overview of SIGN 97.

METHODS A systematic review of evidence-based literature was performed using Medline and Cochrane databases. Studies reviewed include randomized controlled.

Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.

Lipid Disorders and Management in Diabetes

Cholesterol quintile (mg/dL)

No more broken hearts Presented by: Jeffrey Avila Janae Gonzales Burt Matthews Quantitative Trait Loci Analysis for Plasma HDL-Cholesterol Concentrations.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

 2010 Wellsource, Inc. All rights reserved. Polyunsaturated Fats and CHD Harvard Study 2010.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

Better Health. No Hassles. HIGH BLOOD CHOLESTEROL Cholesterol is found in every cell in our body. Cholesterol is used to build healthy cells, as well as.

Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.

Date of download: 6/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Homocysteine-Lowering With Folic Acid.

Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11): doi: /

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Hypercholesterolemia Enhances Thromboembolism in Arterioles but Not Venules by Martijn A.W. Broeders, Geert Jan Tangelder, Dick W. Slaaf, Robert S. Reneman,

Blood Pressure and Lipid Trials: Rationale, Importance and Design

The ALERT Trial.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

The Importance of Adequately Powered Studies

Anti-Hypercholesterolemic Agents

Copyright © 2000 American Medical Association. All rights reserved.

AIM HIGH Niacin plus Statin to prevent vascular events

APOC3 LOF heterozygotes have lower IVD and IHD risks due to lower RC

First time a CETP inhibitor shows reduction of serious CV events

Copyright © 2012 American Medical Association. All rights reserved.

Calcification burden of the femoropopliteal artery demonstrating progression from a healthy artery with no calcification (0) to advanced calcific deposits.

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Anti-Hypercholesterolemic Agents

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

Prospective associations of plasma phospholipid trans/trans-18:2 with total mortality, CVD and CHD before and after mutual adjustment without correction.

Infusion of CSL112 increases total cholesterol efflux capacity (CEC) regardless of baseline functional apolipoprotein A-I (apoA-I) activity. Infusion of.

Arterioscler Thromb Vasc Biol

Arterioscler Thromb Vasc Biol

by John T. Wilkins, Hongyan Ning, Neil J. Stone, Michael H

Biosynthesis and Metabolism of Cholesterol

Patient 1: 53-Year-Old Man With CVD Risk Factors

William Insull, MD The American Journal of Medicine

Diet-heart issues in a pharmacological era

Advances in Hypertriglyceridemia Treatment

Nat. Rev. Cardiol. doi: /nrcardio

David J.A. Jenkins et al. JACC 2018;71:

Cause of death Treatment-arm events, % (n=45 054)

The Mediterranean Diet, its Components, and Cardiovascular Disease

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

David J.A. Jenkins et al. JACC 2018;71:

Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,

Forest plot of randomised controlled trials investigating the effects of pasta in the context of low-GI dietary patterns on body weight (kg). n=2448. Forest.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Section 6: Update on lipid treatment guidelines

Presentation transcript:

Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279) n-3 fatty acids0.44 ( ) n=3 (1,348/1,349) Fibrates0.98 ( ) n=12 (9,873/11,496) Resins0.71 ( ) n=8 (3,280/3,257 Hormones1.04 ( ) n=8 (4,516/9,039) Niacin acids0.85 ( ) n=2 (1,196/2,932) Diet0.91 ( ) n=16 (48,481/59,042) Risk Ratio % 95% CI BenefitHarm Arterioscler Thromb Vasc Biol. 1999;19:

Risk Ratio for Overall Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.79 ( ) n=13 (16,228/11,279) n-3 fatty acids0.66 ( ) n=3 (1,348/1,349) Fibrates1.06 ( ) n=12 (9,873/11,496) Resins0.85 ( ) n=8 (3,280/3,257 Hormones1.09 ( ) n=8 (4,516/9,039) Niacin acids0.96 ( ) n=2 (1,196/2,932) Diet0.97 ( ) n=16 (48,441/59,042) Risk Ratio % 95% CI BenefitHarm Arterioscler Thromb Vasc Biol. 1999;19:

Risk Ratio for Mortality Other Than From CHD in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.97 ( ) n=13 (16,228/11,279) n-3 fatty acids1.16 ( ) n=3 (1,348/1,349) Fibrates1.16 ( ) n=12 (9,873/11,496) Resins1.07 ( ) n=8 (3,280/3,257 Hormones1.29 ( ) n=8 (4,516/9,039) Niacin acids0.99 ( ) n=2 (1,196/2,932) Diet1.00 ( ) n=16 (48,481/59,042) Risk Ratio % 95% CI BenefitHarm Arterioscler Thromb Vasc Biol. 1999;19: